RIABNI
Clinical safety rating
cautionComprehensive clinical and safety monograph for RIABNI (RIABNI).
Comprehensive clinical and safety monograph for RIABNI (RIABNI).
Non-Hodgkin lymphoma (NHL)Chronic lymphocytic leukemia (CLL)Rheumatoid arthritis (RA) in combination with methotrexateGranulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA)Pemphigus vulgaris (off-label)
Rituximab is a chimeric murine/human monoclonal IgG1 kappa antibody that binds specifically to the CD20 antigen expressed on pre-B and mature B-lymphocytes. Upon binding, it mediates B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
| Metabolism | Rituximab is a monoclonal antibody metabolized via general protein catabolism; no specific metabolic pathway. |
| Excretion | RIABNI (rituximab-abbs) is a chimeric monoclonal antibody. Elimination occurs via nonspecific catabolism and target-mediated clearance. No significant renal or biliary excretion; <1% excreted unchanged in urine. Metabolism is primarily through proteolytic degradation to small peptides and amino acids. |
| Half-life | The terminal elimination half-life is approximately 22 days (range 6-52 days) in patients with rheumatoid arthritis. In B-cell non-Hodgkin lymphoma, median half-life is 8 days after first dose and 15-30 days after subsequent doses due to saturable clearance. Clinical context: prolonged half-life supports weekly or monthly dosing. |
| Protein binding | Rituximab-abbs binds specifically to CD20 antigen on B-cells; plasma protein binding is not relevant for monoclonal antibodies. No significant binding to other serum proteins. The molecule is primarily in the free form in circulation. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 3.0-5.0 L/kg. This large Vd reflects extensive distribution into tissues, including lymphoid organs and bone marrow, due to binding to CD20-positive cells. Central volume is ~2.7 L/m². |
| Bioavailability | RIABNI is administered intravenously only; bioavailability is 100% by this route. No oral formulation exists. |
| Onset of Action | Intravenous administration: depletion of peripheral B cells is detectable within 24 hours; clinical response in rheumatoid arthritis may be observed within 4-8 weeks. For oncology indications, tumor response may be seen after 2-4 cycles (weeks to months). |
| Duration of Action | B-cell depletion persists for 6-9 months after a single course (4 weekly doses) in rheumatoid arthritis, with gradual B-cell recovery starting at 6 months and returning to normal within 12 months. Duration of clinical response varies; in autoimmune indications, effects may last 6-12 months. |
| Molecular Weight | 145,000 Da |
1000 mg intravenously on days 1 and 15 of a 28-day cycle, then every 24 weeks or based on disease activity.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; use with caution in elderly patients due to higher risk of infections. |
| 1st trimester | Limited human data; animal studies do not indicate direct harmful effects. However, as a monoclonal antibody, it is actively transported across the placenta during the second and third trimesters, not significantly in the first. Use only if clearly needed. |
| 2nd trimester | IgG1 monoclonal antibodies cross the placenta increasingly after 20 weeks gestation. Potential fetal B-cell depletion; avoid live vaccines in infants exposed in utero. Use only if benefit outweighs risk. |
| 3rd trimester | Significant placental transfer occurs, leading to therapeutic levels in the fetus. Neonates may have transient B-cell depletion and increased infection risk. Consider delaying live vaccines for at least 6 months. Use only if clearly indicated. |
Clinical note
Comprehensive clinical and safety monograph for RIABNI (RIABNI).
| Placental transfer | RIABNI (rituximab-abbs) is an IgG1 monoclonal antibody. It is actively transported across the placenta via FcRn receptors, especially in the second and third trimesters. Placental transfer increases with gestational age; fetal levels can reach maternal levels at term. |
| Breastfeeding | It is not known whether RIABNI is excreted in human milk. Human IgG is present in breast milk; however, the absorption and potential for systemic exposure in the breastfed infant are low. Consider the benefits of breastfeeding, the importance of the drug to the mother, and the potential for adverse effects in the infant (e.g., B-cell depletion). In general, monoclonal antibodies with a large molecular weight are unlikely to be significantly absorbed orally. |
| Lactation Rating | L3 - Probably Compatible |
| Teratogenic Risk | RIABNI (rituximab-abbs), a CD20-directed cytolytic antibody, is an IgG1 with potential transplacental transfer, increasing from second trimester. First trimester: limited data, theoretical risk of B-cell depletion. Second/third trimesters: risk of neonatal B-cell lymphopenia and immunosuppression; advise avoiding live vaccines in infants. |
| Fetal Monitoring | Monitor for infusion reactions, infections. In pregnancy, consider fetal ultrasound for growth and anomalies. Neonatal monitoring for B-cell counts, immunoglobulin levels, and infection risk. |
| Fertility Effects | Rituximab may cause reversible B-cell depletion, but no evidence of permanent fertility impairment. Studies in animals show no adverse effects on fertility. |
■ FDA Black Box Warning
Fatal infusion reactions, severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), and hepatitis B reactivation have been reported.
| Serious Effects |
Known hypersensitivity to rituximab or any component of the formulationActive severe infections (e.g., hepatitis B, tuberculosis, sepsis)
| Precautions | Infusion reactions: premedicate with antihistamines and corticosteroids., Hepatitis B reactivation: screen all patients; monitor during and after therapy., Progressive multifocal leukoencephalopathy (PML): discontinue if suspected., Cardiac adverse reactions: monitor patients with pre-existing cardiac conditions., Bowel obstruction: report in patients with NHL. |
| Food/Dietary | No specific food interactions are known. Grapefruit and other CYP3A4 inhibitors or inducers are unlikely to affect rituximab, as it is a monoclonal antibody not metabolized by CYP enzymes. Advise patient to maintain a balanced diet and stay hydrated. |
| Clinical Pearls | RIABNI (rituximab-abbs) is a biosimilar to rituximab, a CD20-directed cytolytic antibody. Administer as IV infusion; premedicate with acetaminophen and diphenhydramine to reduce infusion reactions. Monitor for severe infusion reactions, especially during first infusion. Hepatitis B virus reactivation risk: screen all patients before initiation. Progressive multifocal leukoencephalopathy (PML) risk: monitor for new neurological symptoms. Do not administer live vaccines before or during treatment. For rheumatoid arthritis, combine with methotrexate. For non-Hodgkin lymphoma, consider tumor lysis syndrome prophylaxis. |
| Patient Advice | You will receive this medication as an intravenous infusion, usually over several hours. · You may experience infusion reactions such as fever, chills, or rash; tell your healthcare team immediately. · Report any new or worsening neurological symptoms like confusion, vision changes, or weakness. · Avoid pregnancy during treatment and for 12 months after the last dose. · Do not receive live vaccines while on this medication. · You will be screened for hepatitis B before starting treatment. |
Loading safety data…